Bristol-Myers Squibb (BMY) reported Q2 non-GAAP earnings Thursday of $1.46 per diluted share, down from $2.07 a year earlier.

Analysts polled by FactSet expected $1.07.

Revenue for the quarter ended June 30 was $12.27 billion, up from $12.20 billion a year earlier.

Analysts surveyed by FactSet expected $11.39 billion.

The company lowered its full-year 2025 non-GAAP EPS guidance to a range of $6.35 to $6.65 from the previous range of $6.70 to $7.00. Analysts surveyed by FactSet expect $6.24.

The company increased its full-year 2025 revenue guidance to a range of $46.50 billion to $47.50 billion from prior outlook of $45.80 billion to $46.80 billion. Analysts polled by FactSet expect $46.28 billion.

The company's shares were up 2.8% in recent Thursday premarket activity.